Asenapine, iloperidone and lurasidone: Critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults

Expert Review of Clinical Pharmacology

Volumn 6, Issue 1, 2013, Pages 61-91

  Bobo, William V ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antipsychotic; asenapine; iloperidone; lurasidone; schizoaffective disorder; schizophrenia

Indexed keywords

ASENAPINE; CLARITHROMYCIN; DILTIAZEM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; ILOPERIDONE; KETOCONAZOLE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RIFAMPICIN; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ANXIETY; AREA UNDER THE CURVE; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPESTHESIA; INSOMNIA; KIDNEY DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PROPENSITY SCORE; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SMOKING; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STEADY STATE; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84871948752     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.70     Document Type: Review

References (107)

1. van Os J, Kapur S. Schizophrenia. Lancet 374(9690), 635-645 (2009
2. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. 26(1), 25-40 (2003 (Pubitemid 36384346)
3. Priebe S. Social outcomes in schizophrenia. Br. J. Psychiatry. SUPPL50, s15-s20 (2007 (Pubitemid 47204550)
4. Cook JA, Razzano L. Vocational rehabilitation for persons with schizophrenia: Recent research and implications for practice. Schizophr. Bull. 26(1), 87-103 (2000 (Pubitemid 30317694)
5. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 177, 212-217 (2000
6. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150(6), 1115-1121 (2005 (Pubitemid 41773510)
7. Hor K, Taylor M. Suicide and schizophrenia: A systematic review of rates and risk factors. J. Psychopharmacol. (Oxford) 24(SUPPL4), 81-90 (2010
8. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr.Bull. 30, 193-217 (2004 (Pubitemid 38828528)
9. Lehman AF, Lieberman JA, Dixon LB et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161(SUPPL2), 1-56 (2004
10. Meltzer HY, Bobo WV. Antipsychotic and anticholinergic drugs. In: New Oxford Textbook of Psychiatry. Gelder MG, Jose Lopez-Ibor J, Andreasen NC (Eds). Oxford University Press, Oxford, UK (2008
11. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302(1), 381-389 (2002 (Pubitemid 34680462)
12. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 373(9657), 31-41 (2009
13. Leucht S, Tardy M, Komossa K et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet 379(9831), 2063-2071 (2012
14. McEvoy JP, Lieberman JA, Stroup TS et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163(4), 600-610 (2006 (Pubitemid 44464569)
15. Lewis SW, Barnes TR, Davies L et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 32(4), 715-723 (2006 (Pubitemid 44412859)
16. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251(1), 238-246 (1989
17. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68(1), 29-39 (2000
18. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/ serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 25(6), 904-914 (2001 (Pubitemid 34031895)
19. Kongsamut S, Roehr JE, Cai J et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur. J. Pharmacol. 317(2-3), 417-423 (1996 (Pubitemid 27014051)
20. Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124(1-2), 57-73 (1996 (Pubitemid 26112775)
21. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. (Oxford) 23(1), 65-73 (2009
22. Ghanbari R, El Mansari M, Shahid M, Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur. Neuropsychopharmacol. 19(3), 177-187 (2009
23. Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-Histamine receptor affinity predicts short-Term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3), 519-526 (2003
24. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-Induced weight gain and diabetes mellitus. Drug Metab. Pharmacokinet. 20(5), 368-378 (2005
25. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev. Neurother. 7(7), 829-839 (2007 (Pubitemid 47037723)
26. Ishibashi T, Horisawa T, Tokuda K et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 334(1), 171-181 (2010
27. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J. Clin. Pharmacol. 35(7), 713-720 (1995
28. Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab. 11(6), 516-525 (2010
29. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry 26(3), 553-560 (2002 (Pubitemid 34252950)
30. van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, Spaans E, Peeters PA, Delbressine LP, van Iersel ML. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab. Dispos. 39, 580-590 (2011
31. Peeters P, Bockbrader H, Spaans E et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin. Pharmacokinet. 50(7), 471-481 (2011
32. Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr. Dis. Treat. 8, 155-168 (2012
33. Meyer JM, Loebel AD, Schweizer E. Lurasidone: A new drug in development for schizophrenia. Expert Opin. Investig. Drugs 18(11), 1715-1726 (2009
34. Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr. Dis. Treat. 5, 483-490 (2009
35. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- And ziprasidonecontrolled trial of iloperidone in patients with acute exacerbations of schizophrenia. J. Clin. Psychopharmacol. 28(2 SUPPL1), S20-S28 (2008 (Pubitemid 351397673)
36. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338). National Institute of Mental Health, Rockville, MD, 218-222 (1976
37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261-276 (1987 (Pubitemid 18039085)
38. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 3(4), 247-251 (1990 (Pubitemid 20228720)
39. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. J. Clin. Psychopharmacol. 28(2 SUPPL1), S4-S11 (2008 (Pubitemid 351397671)
40. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol.Rep. 10, 799-812 (1962
41. Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short-Term treatment of schizophrenia: A post hoc analysis of pooled patient data from four phase III, placebo- And active-controlled trials. Hum. Psychopharmacol. 27(1), 24-32 (2012
42. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- And risperidonecontrolled trial. J. Clin. Psychiatry 68(10), 1492-1500 (2007 (Pubitemid 350073395)
43. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- And haloperidolcontrolled trial in patients with acute exacerbation of schizophrenia. J. Clin. Psychopharmacol. 30(2), 106-115 (2010
44. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J. Clin. Psychiatry 58(12), 538-546 (1997 (Pubitemid 28100274)
45. Citrome L. Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed secondgeneration antipsychotic. Int. J. Clin. Pract. 63(12), 1762-1784 (2009
46. Citrome L. Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int. J. Clin. Pract. 65(2), 189-210 (2011
47. Nakamura M, Ogasa M, Guarino J et al. Lurasidone in the treatment of acute schizophrenia: A double-blind, placebocontrolled trial. J. Clin. Psychiatry 70(6), 829-836 (2009
48. Meltzer HY, Cucchiaro J, Silva R et al. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- And olanzapine-controlled study. Am. J. Psychiatry 168(9), 957-967 (2011
49. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. SUPPL212, 11-19 (1970
50. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J. Nerv. Ment. Dis. 173(6), 353-357 (1985 (Pubitemid 15079180)
51. Kane JM. Lurasidone: A clinical overview. J. Clin. Psychiatry 72(SUPPL1), 24-28 (2011
52. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59(SUPPL20), 22-33; quiz 34 (1998
53. Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Des. Devel. Ther. 6, 107-115 (2012
54. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979 (Pubitemid 9136500)
55. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-Term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. J. Clin. Psychopharmacol. 28(2 SUPPL1), S29-S35 (2008 (Pubitemid 351397674)
56. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-Term treatment. J. Clin. Psychiatry 72(3), 349-355 (2011
57. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-Term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 43(4), 138-146 (2010
58. Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-Term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: An extension study. Pharmacopsychiatry 45(5), 196-203 (2012
59. Buchanan RW, Panagides J, Zhao J et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J. Clin. Psychopharmacol. 32(1), 36-45 (2012
60. de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology (Berl.) 162(1), 24-28 (2002 (Pubitemid 34639552)
61. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med. Care 34(3), 220-233 (1996 (Pubitemid 126433231)
62. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol. Bull. 25(2), 159-163 (1989 (Pubitemid 19273137)
63. Citrome L, Cucchiaro J, Sarma K et al. Long-Term safety and tolerability of lurasidone in schizophrenia: A 12-month, double-blind, active-controlled study. Int. Clin. Psychopharmacol. 27(3), 165-176 (2012
64. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. J. Clin. Psychopharmacol. 28(2 SUPPL1), S12-S19 (2008 (Pubitemid 351397672)
65. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-analysis. CNS Drugs 26(9), 733-759 (2012
66. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr. Res. 76(2-3), 247-265 (2005 (Pubitemid 40804771)
67. Barnes TR. A rating scale for drug-Induced akathisia. Br. J. Psychiatry 154, 672-676 (1989 (Pubitemid 19154942)
68. Buchanan RW. Persistent negative symptoms in schizophrenia: An overview. Schizophr. Bull. 33(4), 1013-1022 (2007 (Pubitemid 47216643)
69. Keefe RS, Bilder RM, Davis SM et al.; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64(6), 633-647 (2007 (Pubitemid 46878665)
70. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr. Bull. 25(2), 201-222 (1999 (Pubitemid 29272501)
71. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8(3), 457-472 (2005 (Pubitemid 41002500)
72. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am. J. Psychiatry 158(4), 518-526 (2001 (Pubitemid 32289814)
73. Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005 (Pubitemid 41345943)
74. Davis JM, Chen N, Glick ID. A metaanalysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60(6), 553-564 (2003
75. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin. Pharmacother. 10(12), 1917-1928 (2009
76. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J. Clin. Psychiatry 60(SUPPL10), 5-14 (1999 (Pubitemid 29237170)
77. Kane JM, Barnes TR, Correll CU et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: A post hoc analysis of pooled data from short- And long-Term aripiprazole trials. J. Psychopharmacol. (Oxford) 24(7), 1019-1029 (2010
78. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16(1), 23-45 (2002 (Pubitemid 34151336)
79. Glassman AH, Bigger JT Jr. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry 158(11), 1774-1782 (2001 (Pubitemid 33054769)
80. Casey DE, HauPTDW, Newcomer JW et al. Antipsychotic-Induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry 65(SUPPL7), 4-18; quiz 19 (2004
81. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-Time use in children and adolescents. JAMA 302(16), 1765-1773 (2009
82. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: An age-related association. Ann. Pharmacother. 42(9), 1316-1322 (2008
83. Kahn RS, Fleischhacker WW, Boter H et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 371(9618), 1085-1097 (2008 (Pubitemid 351418005)
84. Bobo WV, Bonaccorso S, Jayathilake K, Meltzer HY. Prediction of long-Term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. Psychiatry Res. 189(2), 200-207 (2011
85. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann. Clin. Psychiatry 23(1), 40-47 (2011
86. Barbui C, Kikkert M, Mazzi MA et al. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology 42(5), 311-317 (2009
87. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr. Bull. 23(4), 637-651 (1997 (Pubitemid 27485972)
88. Buchanan RW, Kreyenbuhl J, Kelly DL et al.; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 36(1), 71-93 (2010
89. Suppes T, Dennehy EB, Hirschfeld RM et al.; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66(7), 870-886 (2005 (Pubitemid 41032829)
90. Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophr. Bull. 34(2), 275-285 (2008 (Pubitemid 351323339)
91. Bobo WV, Shelton RC. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: Review of efficacy and safety data. Expert Opin. Pharmacother. 10(13), 2145-2159 (2009
92. Bobo WV, Epstein RA, Shelton RC. Acute bipolar depression: A review of the use of olanzapine/fluoxetine. Clin. Med. Insights: Ther. 2, 825-840 (2010
93. Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: A systematic review and meta-analysis. Int. Clin. Psychopharmacol. 27(2), 76-90 (2012
94. Nelson JC, Mankoski R, Baker RA et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-Hoc, pooled analysis of two large, placebo-controlled studies. J. Affect. Disord. 120(1-3), 133-140 (2010
95. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: Update and clinical perspective. Curr. Opin. Psychiatry 24(1), 10-17 (2011
96. Loebel A, Cycchiaro J, Silva R, Sarma K et al. Lurasidone adjunctive to lithium or valproate for the treatment of bipolar depression: Results of a 6-week, doubleblind, placebo-controlled study. Poster presented at: The 165th Annual Meeting of the American Psychiatric Association, PA, USA, 5-9 May 2012.
97. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy for the treatment of bipolar depression: Results of a 6-week, double-blind, placebo-controlled study. Poster presented at: The 165th Annual Meeting of the American Psychiatric Association, PA, USA, 5-9 May 2012.
98. Vieta E, Locklear J, Günther O et al. Treatment options for bipolar depression: A systematic review of randomized, controlled trials. J. Clin. Psychopharmacol. 30(5), 579-590 (2010
99. Meltzer HY. Dimensions of outcome with clozapine. Br. J. Psychiatry. SUPPL(17), 46-53 (1992
100. Lieberman JA, Koreen AR, Chakos M et al. Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiatry 57(SUPPL9), 5-9 (1996 (Pubitemid 26327751)
101. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr. Bull. 23(4), 663-674 (1997 (Pubitemid 27485974)
102. Asenjo LC, Komossa K, Rummel-Kluge C et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. CD006633 (2010
103. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19(SUPPL1), 1-93 (2005 (Pubitemid 40677047)
104. Lavedan C, Licamele L, Volpi S et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 14(8), 804-819 (2009
105. Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry 14(11), 1024-1031 (2009
106. Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 70(6), 801-809 (2009
107. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17(12), 1206-1227 (2012